Advanced search
Publication Cover
Journal of Chemotherapy Volume 36, 2024 - Issue 1
Submit an article Journal homepage
74
Views
0
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

Safety of Sotrovimab use in children with COVID-19: an Italian experience

Elisabetta Venturinia Infectious Disease Unit, Meyer Children's Hospital IRCCS, Florence, Italy
,
Lara Fusania Infectious Disease Unit, Meyer Children's Hospital IRCCS, Florence, Italy
,
Andrea Lo Vecchiob Department of Translational Medical Sciences, Pediatric Infectious Disease Unit, University of Naples Federico II, Naples, Italy
,
Sara Maria Scaranob Department of Translational Medical Sciences, Pediatric Infectious Disease Unit, University of Naples Federico II, Naples, Italy
,
Silvia Garazzinoc Department of Pediatric and Public Health Sciences, Infectious Diseases Unit, Regina Margherita Children’s Hospital, University of Turin, Turin, Italy
,
Giulia Pruccolic Department of Pediatric and Public Health Sciences, Infectious Diseases Unit, Regina Margherita Children’s Hospital, University of Turin, Turin, Italy
,
Daniele Donàd Division of Pediatric Infectious Diseases, Department for Women’s and Children’s Health, University of Padua, Padua, Italy
,
Laura Lancellae IRCCS Bambino Gesù Children Hospital, Rome, Italy
,
Guido Castelli Gattinarae IRCCS Bambino Gesù Children Hospital, Rome, Italy
&
Luisa Gallia Infectious Disease Unit, Meyer Children's Hospital IRCCS, Florence, Italy;f Department of Health Sciences, University of Florence, Florence, ItalyCorrespondence[email protected]
 show all
Pages 45-48 | Received 08 Mar 2023, Accepted 16 Aug 2023, Published online: 21 Aug 2023

References

  • Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N Engl J Med. 2022;386(10):995–998. doi:10.1056/NEJMc2119407.
  • Committee for Medicinal Products for Human Use (CHMP) - EMA. Assessment report: eli lilly and company limited use of bamlanivimab and etesevimab for the treatment of COVID-19. 2021.
  • Wolf J, Abzug MJ, Anosike BI, et al. Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatric Infect Dis Soc. 2022;11(5):177–185. doi:10.1093/jpids/piab124.
  • Heo YA. Sotrovimab: first approval. Drugs. 2022;82(4):477–484. doi:10.1007/s40265-022-01690-7.
  • Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381.
  • Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. doi:10.1056/NEJMoa2107934.
  • Romani L, Calò Carducci FI, Chiurchiù S, et al. Safety of monoclonal antibodies in children affected by SARS-CoV-2 infection. Children (Basel). 2022;9(3):369. doi:10.3390/children9030369.
  • Pruccoli G, Bertorello N, Funiciello E, et al. A single-center experience in treating young children at high risk For severe COVID-19 With sotrovimab. Pediatr Infect Dis J. 2022;41(8):e341–e342. doi:10.1097/INF.0000000000003552.
  • Di Chiara C, Mengato D, De Pieri M, et al. Early use of sotrovimab in children: a case report of an 11-Year-Old kidney transplant recipient infected with SARS-CoV-2. Children (Basel). 2022;9(4):451. doi:10.3390/children9040451.
  • Lanari M, Venturini E, Pierantoni L, et al. Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an italian inter-society consensus statement. Ital J Pediatr. 2022;48(1):7. doi:10.1186/s13052-021-01187-1.
  • Weber SC, Danne F, Kieslich M, et al. Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection. J Heart Lung Transplant. 2022;41(8):1124–1126. doi:10.1016/j.healun.2022.05.003.
  • Rau C, Auer-Hackenberg L, Deubzer HE, et al. Treatment of infants and children With SARS-CoV-2 monoclonal antibodies: a european case series. Pediatr Infect Dis J. 2023;42(2):125–129. doi:10.1097/INF.0000000000003773.
  • Blind JE, Sapko M, Killough A, et al. Implementation and patient outcomes of a pediatric COVID-19 monoclonal antibody program. J Pediatric Infect Dis Soc. 2022;11(12):565–574. doi:10.1093/jpids/piac107.
  • Zaqout A, Almaslamani MA, Chemaitelly H, et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. Int J Infect Dis. 2022;124:96–103. doi:10.1016/j.ijid.2022.09.023.
  • Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;604(7906):553–556. doi:10.1038/s41586-022-04594-4.
  • Food and Drug Administration. FDA updates sotrovimab emergency use authorization. 2022.
  • Martin-Blondel G, Marcelin AG, Soulié C, et al. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with omicron BA.2. J Infect. 2022;85(4):e104–e108.
  • Węcławek-Tompol J, Zakrzewska Z, Gryniewicz-Kwiatkowska O, et al. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a polish national study. J Hematol Oncol. 2022;15(1):71. doi:10.1186/s13045-022-01279-3.
  • Gupta A, Gonzalez-Rojas Y, Juarez E, et al. COMET-ICE investigators. Effect of sotrovimab on hospitalization or death Among high-risk patients With mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.